Extract of Ulmus macrocarpa Hance prevents thrombus formation through antiplatelet activity

Yang,Won-Kyung; Lee,Jung-Jin; Sung,Yoon-Young; Kim,Dong-Seon; Myung,Chang-Seon; Kim,Ho   Kyoung

doi:10.3892/mmr.2013.1581

Extract of Ulmus macrocarpa Hance prevents thrombus formation through antiplatelet activity

Authors:
- Won-Kyung Yang
- Jung-Jin Lee
- Yoon-Young Sung
- Dong-Seon Kim
- Chang-Seon Myung
- Ho Kyoung Kim
View Affiliations

Affiliations: Basic Herbal Medicine Research Group, Korea Institute of Oriental Medicine, Daejeon 305-811, Republic of Korea, Korea Medicine (KM)-Based Herbal Drug Research Group, Korea Institute of Oriental Medicine, Daejeon 305-811, Republic of Korea, Department of Pharmacology, Chungnam National University, College of Pharmacy, Daejeon 305-811, Republic of Korea
Published online on: July 10, 2013 https://doi.org/10.3892/mmr.2013.1581
Pages: 726-730

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ulmus macrocarpa Hance (Ulmaceae) has been used as a traditional oriental medicine for the treatment of edema, mastitis, gastric cancer and inflammation. The aim of this study was to investigate the effects of Ulmus macrocarpa extract (UME) on thrombus formation in vivo, platelet activation ex vivo and fibrinolytic activity in vitro. To identify the antithrombotic activity of UME in vivo, we used an arterial thrombosis model. UME delayed the occlusion time by 13.4 and 13.9 min at doses of 300 and 600 mg/kg, respectively. UME significantly inhibited ex vivo platelet aggregation induced by collagen and adenosine 5'-diphosphate (ADP), respectively, but did not affect the coagulation times following activated partial thromboplastin and prothrombin activation. Therefore, to investigate the antiplatelet effect of UME, the effect of UME on collagen and ADP-induced platelet aggregation in vitro was examined. UME exhibited antiplatelet aggregation activity, induced by ADP and collagen. Furthermore, the fibrinolytic activity of UMEwas investigated. The results showed that UME significantly increased fibrinolysis at 1,000 mg/ml. In conclusion, the results suggested that UME may significantly inhibit artery thrombus formation in vivo, potentially due to antiplatelet activity, and also exhibits potential as a clot‑dissolving agent for thrombolytic therapy.

View Figures

View References

1	Pepine CJ: Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care. Ann Med. 42:19–35. 2010. View Article : Google Scholar : PubMed/NCBI
2	Varon D and Spectre G: Antiplatelet agents. Hematology Am Soc Hematol Educ Program. 267–272. 2009. View Article : Google Scholar
3	Aronow WS: Management of peripheral arterial disease of the lower extremities in elderly patients. J Gerontol A Biol Sci Med Sci. 59:172–177. 2004. View Article : Google Scholar : PubMed/NCBI
4	McNicol A and Israels SJ: Platelets and anti-platelet therapy. J Pharmacol Sci. 93:381–396. 2003. View Article : Google Scholar : PubMed/NCBI
5	Stoyioglou A and Jaff MR: Medical treatment of peripheral arterial disease: a comprehensive review. J Vasc Interv Radiol. 15:1197–1207. 2004. View Article : Google Scholar : PubMed/NCBI
6	Medved L and Nieuwenhuizen W: Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost. 89:409–419. 2003.PubMed/NCBI
7	Collen D and Lijnen HR: Thrombolytic agents. Thromb Haemost. 93:627–630. 2005.PubMed/NCBI
8	Rezkalla SH and Benz M: Antiplatelet therapy from clinical trials to clinical practice. Clin Med Res. 1:101–104. 2003. View Article : Google Scholar : PubMed/NCBI
9	Gum PA, Kottke-Marchant K, Welsh PA, White J and Topol EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 41:961–965. 2003. View Article : Google Scholar : PubMed/NCBI
10	Bhatt DL and Topol EJ: Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2:15–28. 2003. View Article : Google Scholar : PubMed/NCBI
11	Eisert WG: How to get from antiplatelet to antithrombotic treatment. Am J Ther. 8:443–449. 2001. View Article : Google Scholar : PubMed/NCBI
12	Kim KW, Park JS, Kim KS, et al: Inhibition of Ulmus davidiana Planch (Ulmaceae) on bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts. Phytother Res. 22:511–517. 2008.
13	Jun CD, Pae HO, Kim YC, et al: Inhibition of nitric oxide synthesis by butanol fraction of the methanol extract of Ulmus davidiana in murine macrophages. J Ethnopharmacol. 62:129–135. 1998. View Article : Google Scholar : PubMed/NCBI
14	Jin YR, Ryu CK, Moon CK, Cho MR and Yun YP: Inhibitory effects of J78, a newly synthesized 1,4-naphthoquinone derivative, on experimental thrombosis and platelet aggregation. Pharmacology. 70:195–200. 2004. View Article : Google Scholar : PubMed/NCBI
15	Astrup T and Mullertz S: The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys. 40:346–351. 1952. View Article : Google Scholar : PubMed/NCBI
16	Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC and Furie B: Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood. 104:3190–3197. 2004. View Article : Google Scholar : PubMed/NCBI
17	Steinhubl SR and Moliterno DJ: The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs. 5:399–408. 2005. View Article : Google Scholar : PubMed/NCBI
18	Azevedo AP, Farias JC, Costa GC, et al: Anti-thrombotic effect of chronic oral treatment with Orbignya phalerata Mart. J Ethnopharmacol. 111:155–159. 2007. View Article : Google Scholar : PubMed/NCBI
19	Kurz KD, Main BW and Sandusky GE: Rat model of arterial thrombosis induced by ferric chloride. Thromb Res. 60:269–280. 1990. View Article : Google Scholar : PubMed/NCBI
20	Lockyer S and Kambayashi J: Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis. J Cardiovasc Pharmacol. 33:718–725. 1999. View Article : Google Scholar : PubMed/NCBI
21	Furie B and Furie BC: Thrombus formation in vivo. J Clin Invest. 115:3355–3362. 2005. View Article : Google Scholar : PubMed/NCBI
22	Farrehi PM, Ozaki CK, Carmeliet P and Fay WP: Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation. 97:1002–1008. 1998. View Article : Google Scholar : PubMed/NCBI
23	Cui X, Sakaguchi T, Shirai Y and Hatakeyama K: Orally administered Panax ginseng extract decreases platelet adhesiveness in 66% hepatectomized rats. Am J Chin Med. 27:251–256. 1999.
24	Park HJ, Rhee MH, Park KM, Nam KY and Park KH: Effect of non-saponin fraction from Panax ginseng on cGMP and thromboxane A2 in human platelet aggregation. J Ethnopharmacol. 49:157–162. 1995. View Article : Google Scholar : PubMed/NCBI
25	Yun YP, Do JH, Ko SR, et al: Effects of Korean red ginseng and its mixed prescription on the high molecular weight dextran-induced blood stasis in rats and human platelet aggregation. J Ethnopharmacol. 77:259–264. 2001. View Article : Google Scholar : PubMed/NCBI
26	Baruah DB, Dash RN, Chaudhari MR and Kadam SS: Plasminogen activators: a comparison. Vascul Pharmacol. 44:1–9. 2006. View Article : Google Scholar : PubMed/NCBI